Evidence map›Paper›PMID 30940126›Full record

ArticleBMC pulmonary medicine2019

Combination of clinical symptoms and blood biomarkers can improve discrimination between bacterial or viral community-acquired pneumonia in children.

Mejbah U Bhuiyan, Christopher C Blyth, Rachel West, Jurissa Lang, Tasmina Rahman, Caitlyn Granland, Camilla de Gier, Meredith L Borland, Ruth B Thornton, Lea-Ann S Kirkham and 5 more

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Antibiotic failure: Beyond antimicrobial resistance.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mejbah U BhuiyanDivision of Paediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia. mejbah.bhuiyan@uwa.edu.au.ORCID http://orcid.org/0000-0002-8274-6265
Christopher C BlythDivision of Paediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia.
Rachel WestWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Jurissa LangDepartment of Microbiology, PathWest Laboratory Medicine WA, Perth, Australia.
Tasmina RahmanWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Caitlyn GranlandWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Camilla de GierWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Meredith L BorlandPerth Children's Hospital, Perth, Australia.
Ruth B ThorntonWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.
Lea-Ann S KirkhamDivision of Paediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia.
Andrew MartinPerth Children's Hospital, Perth, Australia.
Peter C RichmondDivision of Paediatrics, School of Medicine, Faculty of Health and Medical Sciences, The University of Western Australia, Perth, Australia.
David W SmithDepartment of Microbiology, PathWest Laboratory Medicine WA, Perth, Australia.
Adam JaffeSchool of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia.
Thomas L SnellingWesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDifferentiating bacterial from viral pneumonia is important for guiding targeted management and judicious use of antibiotics. We assessed if clinical characteristics and blood inflammatory biomarkers could be used to distinguish bacterial from viral pneumonia.

methodsWestern Australian children (≤17 years) hospitalized with radiologically-confirmed community-acquired pneumonia were recruited and clinical symptoms and management data were collected. C-reactive protein (CRP), white cell counts (WCC) and absolute neutrophil counts (ANC) were measured as part of routine care. Clinical characteristics and biomarker levels were compared between cases with definite bacterial pneumonia (clinical empyema and/or bacteria detected in blood or pleural fluid), presumed viral pneumonia (presence of ≥1 virus in nasopharyngeal swab without criteria for definite bacterial pneumonia), and other pneumonia cases (pneumonia in the absence of criteria for either definite bacterial or presumed viral pneumonia). The area-under-curve (AUC) of the receiver operating characteristic (ROC) curve for varying biomarker levels were used to characterise their utility for discriminating definite bacterial from presumed viral pneumonia. For biomarkers with AUC > 0.8 (fair discriminator), Youden index was measured to determine the optimal cut-off threshold, and sensitivity, specificity, predictive values (positive and negative) were calculated. We investigated whether better discrimination could be achieved by combining biomarker values with the presence/absence of symptoms.

resultsFrom May 2015 to October 2017, 230 pneumonia cases were enrolled: 30 with definite bacterial pneumonia, 118 with presumed viral pneumonia and 82 other pneumonia cases. Differences in clinical signs and symptoms across the groups were noted; more definite bacterial pneumonia cases required intravenous fluid and oxygen supplementation than presumed viral or other pneumonia cases. CRP, WCC and ANC were substantially higher in definite bacterial cases. For a CRP threshold of 72 mg/L, the AUC of ROC was 0.82 for discriminating definite bacterial pneumonia from presumed viral pneumonia. Combining the CRP with either the presence of fever (≥38

conclusionsCombining elevated CRP with the presence or absence of clinical signs/ symptoms differentiates definite bacterial from presumed viral pneumonia better than CRP alone. Further studies are required to explore combination of biomarkers and symptoms for use as definitive diagnostic tool.

Indexed as

Area Under CurveAustraliaBacteriaBiomarkersCalcitoninCase-Control StudiesChildChild, PreschoolCommunity-Acquired InfectionsC-Reactive ProteinFemaleHumansInfantLeukocyte CountLogistic ModelsMaleBiomarkersCalcitoninC-Reactive ProteinBacteriaBlood biomarkerChildrenC-reactive proteinPneumoniaVirus

Identifiers

PMID30940126
PMCPMC6444754

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.